| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Etelcalcetide HCl (formerly known as ONO-5163; AMG-416, KAI-4169 and velcalcetide, Parsabiv), the hydrochloride salt of Etelcalcetide, is an agonist of calcium-sensing receptor that has been approved by FDA in 2017 as a calcimimetic drug for the treatment of secondary hyperparathyroidism in CKD (chronic kidney disease) patients undergoing hemodialysis.
| References | |
|---|---|
| Additional Infomation |
See also: Etelcalcetide (has active moiety).
Drug Indication Parsabiv is indicated for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease (CKD) on haemodialysis therapy. |
| Molecular Formula |
C38H74CLN21O10S2
|
|---|---|
| Molecular Weight |
1084.72
|
| Exact Mass |
1083.505
|
| Elemental Analysis |
C, 38.22; H, 6.50; Cl, 11.88; N, 24.63; O, 13.40; S, 5.37
|
| CAS # |
1334237-71-6
|
| Related CAS # |
Etelcalcetide; 1262780-97-1
|
| PubChem CID |
71515466
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
19
|
| Hydrogen Bond Acceptor Count |
17
|
| Rotatable Bond Count |
36
|
| Heavy Atom Count |
72
|
| Complexity |
1910
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
Cl.S(C[C@H](C(N[C@H](C)C(N[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@H](C)C(N[C@@H](C(N)=O)CCC/N=C(\N)/N)=O)=O)CCC/N=C(\N)/N)=O)CCC/N=C(\N)/N)=O)CCC/N=C(\N)/N)=O)=O)NC(C)=O)SC[C@@H](C(=O)O)N
|
| InChi Key |
KHQMSZGKHGQUHG-WZDHWKSBSA-N
|
| InChi Code |
InChI=1S/C38H73N21O10S2.ClH/c1-18(28(62)56-22(27(40)61)8-4-12-49-35(41)42)53-30(64)23(9-5-13-50-36(43)44)58-32(66)25(11-7-15-52-38(47)48)59-31(65)24(10-6-14-51-37(45)46)57-29(63)19(2)54-33(67)26(55-20(3)60)17-71-70-16-21(39)34(68)69;/h18-19,21-26H,4-17,39H2,1-3H3,(H2,40,61)(H,53,64)(H,54,67)(H,55,60)(H,56,62)(H,57,63)(H,58,66)(H,59,65)(H,68,69)(H4,41,42,49)(H4,43,44,50)(H4,45,46,51)(H4,47,48,52);1H/t18-,19-,21+,22-,23-,24-,25-,26-;/m1./s1
|
| Chemical Name |
(2R)-3-[[(2S)-2-acetamido-3-[[(2R)-1-[[(2R)-1-[[(2R)-1-[[(2R)-1-[[(2R)-1-[[(2R)-1-amino-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-oxopropyl]disulfanyl]-2-aminopropanoic acid;hydrochloride
|
| Synonyms |
Velcalcetide HCl; AMG-416 HCl; ONO5163; ONO-5163 HCl; AMG416; KAI 4169; KAI4169; AMG 416; KAI-4169; ONO 5163; Etelcalcetide; Velcalcetide; trade name Parsabiv; Telcalcetide; Ac-D-Cys-D-Ala-D-Arg-D-Arg-D-Arg-D-Ala-D-Arg-NH2 HCl
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (73.89 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.9219 mL | 4.6095 mL | 9.2190 mL | |
| 5 mM | 0.1844 mL | 0.9219 mL | 1.8438 mL | |
| 10 mM | 0.0922 mL | 0.4609 mL | 0.9219 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT03969329 | Recruiting | Drug: Etelcalcetide | Secondary Hyperparathyroidism | Amgen | December 20, 2019 | Phase 3 |
| NCT03633708 | Recruiting | Drug: Etelcalcetide | Secondary Hyperparathyroidism Chronic Kidney Disease |
Amgen | April 29, 2019 | Phase 3 |
| NCT03960437 | Completed | Drug: Etelcalcetide | Renal Osteodystrophy Vascular Calcification |
Thomas Nickolas, MD MS | September 6, 2018 | Phase 2 |
| NCT03795558 | Completed | Drug: Etelcalcetide | End Stage Renal Disease | Prim. Priv. Doz. Dr. Daniel Cejka | May 1, 2019 | Phase 2 |
| NCT01254565 | Completed | Drug: Etelcalcetide Drug: Placebo |
Secondary Hyperparathyroidism | KAI Pharmaceuticals | February 20, 2011 | Phase 2 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA